Vulvovaginal Candidiasis Treatment Market Size, Share to 2028

Global Vulvovaginal Candidiasis Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Oral, Intravenous and Topical), By Drug Class, By Regional Outlook and Forecast, 2022 - 2028

Published Date: November-2022 | Number of Pages: 226 | Format: PDF | Report ID: KBV-21605

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


COVID-19

Get in-depth analysis of the COVID-19 impact on the Vulvovaginal Candidiasis Treatment Market

Market Report Description

The Global Vulvovaginal Candidiasis Treatment Market size is expected to reach $1.3 billion by 2028, rising at a market growth of 4.6% CAGR during the forecast period.

Vulvovaginal Candidiasis is generally caused due to candida Albicans or candida species or yeast. Some of the symptoms of vulvovaginal candidiasis include abnormal vaginal discharge, vaginal soreness, dyspareunia, external dysuria, and pruritis. As per the data provided by the Centers for Disease Control and Prevention, around 75% of women are predicted to have vulvovaginal candidiasis at least one time and 40%–45% of women may have the condition two or more times. The condition is classified as complicated or uncomplicated on the basis of clinical presentation, host factors, microbiology, and response to therapy.

Vulvovaginal Candidiasis Treatment Market Size - Global Opportunities and Trends Analysis Report 2018-2028

The condition generally rises the need to consider a gynecologist or nurse practitioner. Vulvovaginal Candidiasis can be diagnosed and managed by antifungal medications. Although vulvovaginal candidiasis could be treated in a few days, in cases of complicated situations the treatment could be for a longer period.

Patient awareness is very crucial in this condition. Though vulvovaginal candidiasis is not life-threatening it is essential to have adequate medication over time as it may become worse and lead to withdrawal from sexual activities out of embarrassment. Malignancy, abuse, trauma, inflammatory bowel disease, sexual transmission of infections, and immune disease could be some of the reasons for vaginal discomfort. The patients must undergo a complete and careful physical test, and proper ancillary testing to know about the exact reason for the condition for further treatment.

One should undergo the diagnosis of vulvovaginal candidiasis if the person feels pain, redness, or swelling in the vaginal area. The condition of vulvovaginal candidiasis is linked to normal vaginal pH which is 4.5. Using 10% of KOH in wet preparations helps in improving the visualization of mycelia and yeast via disrupting cellular material which may hide the pseudohyphae or yeast. It is important for all women having symptoms of vulvovaginal candidiasis to undergo an examination of the wet mount with KOH preparation and get treatment on time.

COVID-19 Impact Analysis

The widespread novel coronavirus all over the world has slightly impacted the growth of the vulvovaginal candidiasis treatment market. The demand for drugs for vulvovaginal candidiasis was high due to the rising prevalence of candidiasis among patients who have suffered from COVID-19. This is because of the rise in healthcare-associated infections and bloodstream infections, especially among those who were admitted to hospitals. Owing to all these elements, the vulvovaginal candidiasis market has quickly recovered after the first quarter of 2020 and is further anticipated to continue to grow.

Market Growth Factors

Growing spending on research & development and expansion of product portfolio

The market has been witnessing the introduction of various safe & effective antifungal agents. Some of the effective antifungal agents available in the market are terbinafine, fluconazole, and itraconazole. The pharmaceutical industries are increasing the expenditure on research & development intending to expand their product portfolio for anti-infective drugs. Most of the market players are focusing on the development of effective therapeutic agents for patients with weak immunity systems to cure fungal infections such as vulvovaginal candidiasis.

Rising prevalence of diabetes

The prevalence of diabetes is growing continuously all over the world. According to the data provided by WHO, in 1980, patients with diabetes was around 108 million, which rose to 422 million in 2014. The prevalence has been growing more rapidly in low-income and middle-income nations as compared to high-income nations. Diabetes is one of the reasons for various serious issues such as stroke, heart failure, blindness, kidney failure, and others. In 2014, about 8.5% of adults above the age of 18 were diabetic. As the prevalence of diabetes across the world is growing, the cases of vulvovaginal candidiasis are also predicted to increase. This would result in market growth for the vulvovaginal candidiasis treatment in the upcoming years.

Market Restraining Factor

Side effects of consumption of medicines such as fluconazole

Medicines such as fluconazole are antifungal medications prescribed to cure candida fungal infections such as vulvovaginal candidiasis. The consumption of fluconazole may lead to drug interaction with various blood thinners, antibiotics, sedatives, diuretics, antiseizure, and various other medications. Also, various cautions mentioned on the medicines are applied to individuals having liver disorders or any other diseases which could lead to the side effect of consuming such conditions.

Distribution Channel Outlook

On the basis of distribution channel, the vulvovaginal candidiasis treatment market is divided into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, the retail pharmacy segment witnessed the highest revenue share in the vulvovaginal candidiasis treatment market. The disease treatment takes short as well as long-term support of medications which raises the sale of treatment drugs from retail pharmacies.

Vulvovaginal Candidiasis Treatment Market Share and Industry Analysis Report 2021

Route of Administration Outlook

By route of administration, the vulvovaginal candidiasis treatment market is fragmented into oral, intravenous and topical. The topical segment covered a significant revenue share in the vulvovaginal candidiasis treatment market in 2021. This is attributable to the availability of topical products such as prescription formulations and over-the-counter. Topical OTCs include Miconazole cream, Tioconazole ointment, and Clotrimazole cream and prescription formulations include Terconazole cream and Butoconazole cream.

Drug Class Outlook

Based on drug class, the vulvovaginal candidiasis treatment market is segmented into clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole and others. In 2021, the fluconazole segment dominated the vulvovaginal candidiasis treatment market with the maximum revenue share. Fungal diseases pose a crucial threat to public health for certain reasons, due to which the market players across the globe are focused on research & development of clinical use of fluconazole.

Vulvovaginal Candidiasis Treatment Market Report Coverage
Report Attribute Details
Market size value in 2021 USD 971.3 Million
Market size forecast in 2028 USD 1.3 Billion
Base Year 2021
Historical Period 2018 to 2020
Forecast Period 2022 to 2028
Revenue Growth Rate CAGR of 4.6% from 2022 to 2028
Number of Pages 226
Number of Tables 388
Report coverage Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling
Segments covered Distribution Channel, Route of Administration, Drug Class, Region
Country scope US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers
  • Growing spending on research & development and expansion of product portfolio
  • Rising prevalence of diabetes
Restraints
  • Side effects of consumption of medicines such as fluconazole

Regional Outlook

Region wise, the vulvovaginal candidiasis treatment market analyzed across North America, Europe, Asia Pacific and LAMEA. The North America region led the vulvovaginal candidiasis treatment market by generating the maximum revenue share in 2021. The main factor resulting in the region’s dominance in the market is the presence of market players such as Johnson & Johnson Services Inc., Pfizer Inc., and others. Moreover, the regional market is expanding due to the rising prevalence of diabetes in the region, which may lead to increased cases of vulvovaginal candidiasis in the North American nations.

Free Valuable Insights: Global Vulvovaginal Candidiasis Treatment Market size to reach USD 1.3 Billion by 2028

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

By Route of Administration

  • Oral
  • Intravenous
  • Topical

By Drug Class

  • Fluconazole
  • Clotrimazole
  • Terconazole
  • Terbinafine
  • Nystatin
  • Ketoconazole
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Bayer AG
  • Bristol Myers Squibb Company
  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC)
  • Basilea Pharmaceutica Ltd.
  • Scynexis, Inc.
  • Grupo Ferrer Internacional S.A.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

North America Vulvovaginal Candidiasis Treatment Market Report 2022-2028

Europe Vulvovaginal Candidiasis Treatment Market Report 2022-2028

Asia Pacific Vulvovaginal Candidiasis Treatment Market Report 2022-2028

LAMEA Vulvovaginal Candidiasis Treatment Market Report 2022-2028

FREQUENTLY ASKED QUESTIONS (FAQ):

The global Vulvovaginal Candidiasis Treatment Market size is expected to reach $1.3 billion by 2028.

Growing spending on research & development and expansion of product portfolio are driving the market in coming years, however, Side effects of consumption of medicines such as fluconazole restraints the growth of the market.

Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.

The Oral market is leading the segment in the Global Vulvovaginal Candidiasis Treatment Market by Route of Administration in 2021; thereby, achieving a market value of $582.8 million by 2028.

The North America market dominated the Global Vulvovaginal Candidiasis Treatment Market by Region in 2021; thereby, achieving a market value of $479.2 million by 2028.

Purchase Report

 3600
 4320
 6048

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities